Annual Meeting

EmailPrint

Type Size

19th European Meeting on Hypertension

June 12 - 16, 2009

Milan Convention Center

Milan, Italy

The annual European Hypertension Meetings offer the highest quality scientific programs related to research in Basic and Clinic areas in Hypertension with State-of-the-Art Lectures, Satellite Symposia, Breakfast Workshops, Working Groups sessions and credits for qualifying as Hypertension Specialists of the European Society of Hypertension.

Early Blood Pressure Control By The Nifedipine Gits/Telmisartan Combination” presented during the Hot Line Session on Saturday 19th June in Oslo

Meeting Highlights - read below the news from the largest annual research and clinical meeting on hypertension
Webcasts - watch the webcast coverage of some of the most important scientific sessions presented during ESH 2009
Teaching Sessions - view the webcasts from these excellent educational sessions
Interviews - short in depth interviews on hot topics from ESH 2009
Podcasts - listen to expert commentaries on the 2009 Annual Meeting key science

ESH 2009 – Best Selected Posters - see the "Best Selected Posters of the Day"

Meeting Highlights

1-18 of 18 results

Guidelines on Hypertension Management Revisited in 2009: ESH Position Statement

The update of the Guidelines on hypertension management will be released in October 2009: at the European Meeting on Hypertension 2009, Prof. Giuseppe Mancia outlines the reasons for the update.

Central Pressure And New Goals: Should Be Hypertension Therapy Priorities

A fundamental change in the way hypertension is measured, and studies to identify evidence-based blood pressure goals have been highlighted as top priorities by one of Sweden’s prominent hypertension specialists, Björn Dahlöf, during the European Meeting on Hypertension.

ESH 2009 – Best Selected Posters

The Best Selected Posters of the Day from the 19th European Meeting on Hypertension.

HIGHCARE: Expedition to Mount Everest Offers New Insights Into Chronic Disease

First-ever ABPM study at high altitude investigating treatment with an ARB suggests telmisartan could be effective at treating hypoxia-induced BP. HIGHCARE 2008 Project: a valid model of hypoxia-related BP alterations, similar to those characterising patients with sleep apnea.

Hypertension And Stroke: Portuguese Cardiologist Takes Action Against Salt

Doctors have successfully introduced measures to reduce salt consumption in Portugal by engaging the food industry, government and – most important – the Portuguese people to bring about change through their study: “Portuguese Action Against Salt And Hypertension” reported to the European Meeting on Hypertension meeting.

Ethnicity: Big Determinant Of Cardiovascular Mortality

Framingham risk scores are out of fashion at a leading research institution in Amsterdam when it comes to assessing cardiovascular risk in South Asian and Black patients. A study presented at the European Society of Hypertension meeting has discovered that race can far outweigh conventional risk factors.

Eight Blood Pressure Genes Bring Promise For Drug Design

Eight human genes have been recognised as modulating blood pressure by a team from London, UK, presenting findings at the European Society of Hypertension's annual conference. The researchers hope that these will provide targets for new drugs to treat hypertension.

Polypill Promising Potential For Primary Prevention of Cardiovascular Disease

A study in India among 2000 healthy volunteers who had risk factors for cardiovascular disease has shown that a capsule containing half doses of five drugs known individually to reduce coronary risks has the potential to make massive reductions in disease among communities where it is used.

Angiotensin AT2 Receptor Agonist: Restorative Role For Patients With Hypertension?

The illusive angiotensin AT2 receptor could become an important new target for therapy in the overall care of patients with hypertension. A leading researcher in cardiovascular medical science has found that by stimulating this receptor his group discovered remarkable regenerative and anti-inflammatory effects.

ADAM Combats Atherosclerosis in EVA

Early Vascular Aging (EVA) is common and needs to be recognised soon enough if your patient's life is to be prolonged, the hypertension conference in Milan heard in a session on coronary risk factors. The remedy for EVA, according to Peter Nilsson, professor of cardiovascular research from Sweden, is to use: ADAM (Aggressive Decrease of Atherosclerosis Modifiers).

Intensive Glycaemic Control: Meta Analysis Confirms Fewer Cardiovascular Events In Type II Diabetes

A leading member of the European Society of Hypertension has given the clear recommendation to clinicians that they should manage hyperglycaema aggressively in patients with Type II diabetes. His comments followed discussions during the annual meeting of the Society held in Milan about the meta-analysis of five big studies recently published in The Lancet which confirms a reduction of cardiovascular events.

Czech Republic Sees Massive Decline In Cardiovascular Deaths With Hypertension Treatment And Awareness

A forty per cent reduction in cardiovascular mortality overall and a sixty per cent fall in stroke deaths between 1985 and 2007 have been revealed by a study in the Czech Republic. The investigators speculate that improvements in blood pressure control and blood pressure levels could be the principal drivers of these changes.

Microalbuminuria: Undervalued As A Risk Assessment Tool

A substantial minority of doctors in five European countries failed to test appropriately for microalbuminuria to assess multiple organ risks among their patients with hypertension, according to a European Society of Hypertension survey. This means that organ damage is often already present by the time such testing is eventually done, according to the survey author.

Drug-Free Blood Pressure Reduction By Catheter Nerve Ablation

Non-pharmacological control of severe, refractory hypertension has been achieved by a team in Australia using a technique which is thought to harnesses the brain’s natural control mechanisms over sympathetic activity. The investigators hold out the hope that this could eventually be used to treat a wider range of high blood pressure, and perhaps avoid the use of drugs.

Hydrochlorothiazide: Not Recommended for First-Line Therapy in Hypertension

A popular diuretic has lost favour with one of New York’s top hypertension experts. Franz Messerli made a cogent argument during a “Late-Breaker” session at the Milan conference for never using hydrochlorothiazide as initial therapy for hypertension.

Hypertension In The Very Elderly Trial (HYVET): Lower Is Better, But Not Too Low

Patients over the age of 80 should be treated for their hypertension just like younger patients, according to updated findings from the international HYVET study. Very elderly patients benefited markedly from blood pressure lowering with indapamide used either as monotherapy or combined with perindopril.

Blood Pressure “Too Low” Can Increase Mortality In Diabetes

Aggressive lowering of blood pressure could put diabetics at increased risk of mortality, according to Josep Redon, MD, Professor of Medicine at the University of Valencia in Spain.

ESH Annual Meeting Chair: Redefines Blood Pressure Targets

“There are new recommended threshold values for systolic and diastolic blood pressure” declared Professor Giuseppe Mancia, Chairman of the 19th European Meeting on Hypertension and Director of Clinical Medicine at Milan-Bicocca University, in an interview at the 2009 Annual Meeting of ESH held in Milan.

Your Name
Your Email
Recipient's Email
Your Comments

Comments*